Muscle Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major muscle spasticity markets reached a value of US$ 3.3 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 6.9 Billion by 2034, exhibiting a growth rate (CAGR) of 8.54% during 2023-2034.

The muscle spasticity market has been comprehensively analyzed in this report titled "Muscle Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Muscle spasticity refers to a condition characterized by involuntary and sustained muscle contractions or spasms. It is a common symptom observed in various neurological disorders that impact the central nervous system, such as multiple sclerosis, spinal cord injury, cerebral palsy, etc. Some of the indications associated with the ailment include involuntary muscle contractions, muscle stiffness and tightness, increased muscle tone, exaggerated reflexes, muscle and joint pain, difficulty with coordinated movements, limited range of motion, etc. These symptoms can vary in intensity and affect different muscle groups, leading to challenges in mobility, posture, and performing activities of daily living. The diagnosis of muscle spasticity involves a comprehensive evaluation by a healthcare professional, typically a neurologist or a physiatrist specializing in rehabilitation medicine. The diagnostic process includes a thorough medical history review, a physical examination to assess muscle tone and reflexes, and neurological tests to check motor function as well as identify any underlying conditions contributing to the condition. Various additional diagnostic tools, such as electromyography (EMG), nerve conduction studies, imaging scans, etc., are also utilized to further evaluate the extent and cause of muscle spasticity.

The increasing cases of stroke that result in brain cell damage as well as disruption of motor control and nerve signaling are primarily driving the muscle spasticity market. In addition to this, the growing prevalence of spinal cord injuries, which can lead to uncontrolled or exaggerated signals to the muscles and loss of inhibitory control, is also creating a positive outlook for the market. Moreover, the widespread adoption of various oral medications, such as baclofen, tizanidine, dantrolene sodium, etc., since they assist in reducing nerve signals that cause muscle contractions, is further bolstering the market growth. Apart from this, the emerging popularity of botulinum toxin injections on account of their several associated benefits, including decreased muscle contractures, improved range of motion, and enhanced functionality, is acting as another significant growth-inducing factor. Additionally, the inflating demand for numerous electrical stimulation techniques, such as functional electrical stimulation (FES) and transcutaneous electrical nerve stimulation (TENS), which deliver controlled electrical impulses to specific muscles, thereby promoting relaxation, is expected to drive the muscle spasticity market during the forecast period.

This report provides an exhaustive analysis of the muscle spasticity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for muscle spasticity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the muscle spasticity market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the muscle spasticity market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the muscle spasticity market

Competitive Landscape:

This report also provides a detailed analysis of the current muscle spasticity marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the muscle spasticity market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the muscle spasticity market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the muscle spasticity market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of muscle spasticity across the seven major markets?
• What is the number of prevalent cases (2018-2034) of muscle spasticity by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of muscle spasticity by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with muscle spasticity across the seven major markets?
• What is the size of the muscle spasticity patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of muscle spasticity?
• What will be the growth rate of patients across the seven major markets?

Muscle Spasticity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for muscle spasticity drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the muscle spasticity market?
• What are the key regulatory events related to the muscle spasticity market?
• What is the structure of clinical trial landscape by status related to the muscle spasticity market?
• What is the structure of clinical trial landscape by phase related to the muscle spasticity market?
• What is the structure of clinical trial landscape by route of administration related to the muscle spasticity market?

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.